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Cytochrome P450 enzymes are heme-depen-
dent monoxygenases that play a central role in
human physiology. Despite the numerous phys-
iological processes that P450 enzymes impact,
the electron donors P450 oxidoreductase and
cytochrome b5 are the only proteins known to
interact with and modulate the activity of ER
microsomal P450s. Here, we report that Dap1/
PGRMC1 is required for ER P450 function in
yeast and humans. We show that S. pombe
Dap1 is a hemoprotein that binds and positively
regulates Cyp51A1 andCyp61A1, twoP450s re-
quired for sterol biosynthesis. Similarly, loss of
human PGRMC1 reduces activity of Cyp51A1,
blocking cholesterol synthesis and increasing
production of toxic sterol intermediates.
PGRMC1 stably binds Cyp51A1 and human
P450s from three additional families including
Cyp3A4, which metabolizes pharmaceutical
compounds. These findings demonstrate that
PGRMC1 is required for P450 activity and sug-
gest that interindividual variation in PGRMC1
functionmay impactmultiple biochemical path-
ways and drug metabolism.
INTRODUCTION
Cytochrome P450 enzymes are heme-dependent monox-
ygenases that participate in the biosynthesis of choles-
terol, steroids, bile acids, vitamin D3, and eicosanoids;
detoxification of xenobiotics; and metabolism of pharma-
ceutical drugs (Nebert and Russell, 2002). The human
genome codes for 57 cytochrome P450 enzymes, and
reduced P450 activity can lead to disease, including con-
genital adrenal hyperplasia and hypercholesterolemia.
Despite the vast array of reactions catalyzed by these en-
zymes in organisms ranging from bacteria to mammals,
the P450 catalytic cycle is remarkably well conserved,Cell Mrequiring one molecule of dioxygen and two electrons
from NADPH for the conversion of each substrate mole-
cule to product (Ortiz de Montellano, 2005). Electron do-
nation to eukaryotic ERmicrosomal P450s occurs primar-
ily through transient interactions with NADPH cytochrome
P450 oxidoreductase and, to a lesser extent, cytochrome
b5 (Guengerich, 1991; Vermilion et al., 1981; Schenkman
and Jansson, 2003). Mammalian mitochondrial P450s in-
teract with the electron-donor proteins adrenodoxin and
adrenodoxin reductase (Ortiz de Montellano, 2005). To
date, these are the only proteins known to interact with
and affect the activity of cytochrome P450s.
The number of P450 enzymes varies widely among spe-
cies. In contrast to humans and Arabidopsis thaliana,
which contain 57 and 246 P450 enzymes, respectively,
the fission yeast Schizosaccharomyces pombe has only
two P450 enzymes, Cyp51A1/Erg11 and Cyp61A1/Erg5
(Nelson et al., 2004a, 2004b). These ER-localized en-
zymes from distinct P450 families are both required for
ergosterol biosynthesis: Erg11 catalyzes the demethyla-
tion of lanosterol, and Erg5 carries out the reduction of
ergosta-5,7,24(28)-trienol (see Figure S1 in the Supple-
mental Data available with this article online) (Lees et al.,
1999). Our recent studies revealed that both erg11+ and
erg5+ are transcriptionally regulated by the fission yeast
sterol regulatory element-binding protein (SREBP), called
Sre1, in response to a decrease in oxygen concentration
(Hughes et al., 2005; Todd et al., 2006). SREBP is a mem-
brane-bound transcription factor that regulates expres-
sion of cholesterol biosynthetic genes and controls lipid
homeostasis in mammalian cells (Espenshade, 2006;
Goldstein et al., 2006). Importantly, fission yeast Sre1 also
controls transcription of cytochrome b5 and cytochrome
b5 reductase, raising the possibility that uncharacterized
Sre1 target genes may be required for P450 function.
One Sre1 target gene that emerged as potentially hav-
ing a role in P450 function was the S. pombe homolog of
mammalian PGRMC1 and S. cerevisiae DAP1 (Falken-
stein et al., 1996; Hand et al., 2003). Human PGRMC1
codes for a 22 kDa ER-membrane protein that contains
a N-terminal transmembrane segment and a C-terminal
cytochrome b5-like domain that binds pentacoordinate
heme (Mifsud and Bateman, 2002; Min et al., 2005; Ghoshetabolism 5, 143–149, February 2007 ª2007 Elsevier Inc. 143
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Synthesis in Fission Yeast
(A) Wild-type and sre1D yeast were grown
±oxygen for 6 hr. Total RNA (5 mg) was sub-
jected to northern analysis (top panel), and
total cell extracts (50 mg) were subjected to im-
munoblot analysis with anti-Sre1 IgG (bottom
panel). P and N denote the membrane-bound
precursor and soluble nuclear form of Sre1,
respectively.
(B) Sterols extracted from log-phase wild-type
and dap1D cells (1 3 108 cells) were analyzed
by gas chromatography and GC-MS. Choles-
terol (5 mg) was added as an internal standard.
Data are the average of three independent
replicates. Error bars equal one standard devi-
ation. Dienol, ergosta-5,7-dienol; trienol, ergo-
sta-5,7,24(28)-trienol.
(C) At time 0, nmt-HA-dap1 cells grown in min-
imal medium lacking thiamine were shifted to
thiamine-containingmedium to turn off expres-
sion of HA-dap1 from the nmt promoter. At the
indicated time points, cells were subjected to
sterol analysis (top panel), and total cell ex-
tracts from the same cultures were subjected
to immunoblot blot analysis with anti-HA-HRP
(bottom panel). Error bars equal one standard
deviation.
(D) Wild-type and dap1D yeast (5 3 103 cells)
containing either no plasmid or a plasmid
expressing HA-dap1 from the constitutive
CaMV promoter were spotted on rich medium
with no additions, 5 nM itraconazole, or 1.6
mM CoCl2 and grown at 30
C for 3 days.et al., 2005). Previous studies demonstrated that overex-
pression of PGRMC1 in cultured cells increases hydroxyl-
ation of progesterone by the cytochrome P450 Cyp21,
and monoclonal antibody to PGRMC1 inhibits this activity
in rat adrenal microsomes (Laird et al., 1988; Min et al.,
2005). In addition, S. cerevisiae DAP1 is required for nor-
mal Erg11 protein levels and ergosterol synthesis in yeast
(Hand et al., 2003; Mallory et al., 2005). These data sug-
gest a role for this family of heme-binding proteins in
regulation of cytochrome P450 enzymes in eukaryotes.
Here, we present evidence demonstrating a direct role
for Dap1/PGRMC1 in cytochrome P450 function. Fission
yeast Dap1 is a hemoprotein that binds and positively reg-
ulates Erg11/Cyp51A1 and Erg5/Cyp61A1, two P450s re-
quired for sterol biosynthesis. Importantly, Dap1 function
is conserved in humans. RNAi-mediated knockdown of
human PGRMC1 reduces activity of Cyp51A1, blocking
cholesterol synthesis and increasing production of toxic
sterol intermediates. PGRMC1 stably binds Cyp51A1
and human P450s from three additional families, suggest-
ing that Dap1/PGRMC1 may function as a general regula-
tor of cytochrome P450s. The presence of PGRMC1
homologs in plants, flies, and worms suggests that this
regulation of cytochrome P450 enzymes may be broadly
conserved among eukaryotes.144 Cell Metabolism 5, 143–149, February 2007 ª2007 ElsevierRESULTS AND DISCUSSION
Our previous microarray analysis revealed that fission
yeast dap1+ (SPAC25B8.01) was coordinately regulated
with P450 enzymes by Sre1 in response to low oxygen
(Todd et al., 2006). To confirm these results, we examined
expression of dap1+ in wild-type and sre1D cells grown in
the presence or absence of oxygen. Expression of dap1+
mRNAwas induced in the absence of oxygen in aSre1-de-
pendentmanner (Figure 1A), consistent with the regulation
of other Sre1 target genes such as sre1+ itself. HMG-CoA
synthase (hcs1+) served as a loading control.
To examine whether dap1+ is required for ergosterol
synthesis in fission yeast, we generated a strain lacking
dap1+ by homologous recombination and analyzed ste-
rols from wild-type and dap1D cells using gas chromatog-
raphy and GC-MS. As observed in S. cerevisiae, dap1D
cells showed defects in sterol synthesis (Mallory et al.,
2005). dap1D cells were viable under normal growth con-
ditions but contained a reduced amount of ergosterol
and elevated amounts of the ergosterol biosynthetic inter-
mediates 24-methylene lanosterol, ergosta-5,7,24(28)-tri-
enol, and ergosta-5,7-dienol, consistent with defects at
the Erg11 and Erg5 enzymatic steps (Figure 1B). Ergo-
sta-5,7-dienol is not a normal pathway intermediate, butInc.
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Binding Protein
(A) Dap1-TAP was affinity purified from 4 3
1010 log-phase yeast cells. Eluted Dap1-TAP
protein complexes were subjected to sucrose
gradient velocity centrifugation. TCA-precipi-
tated fractions were resolved by SDS-PAGE
and visualized by silver staining. Fractions
12–14 from a parallel experiment were pooled
and analyzed by mass spectrometry. Proteins
that copurified with Dap1-TAP are indicated.
* indicates a truncated form of Erg5. Arrow-
head denotes keratin contamination.
(B) Detergent-solubilized extracts from dap1-
HA and dap1-HA erg11-Myc yeast were sub-
jected to immunoprecipitation with monoclo-
nal anti-Myc IgG 9E10. Input (I), unbound (U),
and bound (B) fractions were subjected to
immunoblot analysis with polyclonal anti-Myc
IgG, anti-HA-HRP, or anti-Sre1 IgG. Bound
fractions are 10-fold overloaded as compared
to input and unbound fractions. Sre1 repre-
sents the ER-bound precursor form of the
protein.
(C) Detergent-solubilized extracts from dap1-
HA and dap1-HA erg5-TAP yeast were sub-
jected to purification with IgG-Sepharose. In-
put (I), unbound (U), and bound (B) fractions
were subjected to immunoblot analysis with
rabbit IgG, anti-HA-HRP, or anti-Sre1 IgG.forms when Erg5 is inhibited (Figure S1) (Skaggs et al.,
1996). To determine whether the metabolic flux through
these enzymatic steps is reduced as a direct result of
Dap1 absence, we generated nmt-dap1+, a yeast strain
expressing dap1+ under control of the thiamine-repress-
ible nmt1+ promoter. Addition of thiamine to nmt-dap1+
cells resulted in a time-dependent loss of Dap1 protein
(Figure 1C, lower panel). Sterol analysis at different times
after thiamine addition revealed that, upon loss of Dap1,
cells accumulated 24-methylene lanosterol, ergosta-
5,7,24(28)-trienol, and ergosta-5,7-dienol, substrates for
Erg11 and Erg5. Consistent with this role in sterol synthe-
sis, dap1D cells are sensitive to the inhibitors of sterol syn-
thesis itraconazole and CoCl2 (Figure 1D). These data
demonstrate that Dap1 is required in vivo for the activity
of Erg11 and Erg5, the entire complement of cytochrome
P450 enzymes in fission yeast. The low sequence identity
(23%) between these two enzymes from different P450
families suggests that Dap1 may be a general factor
required for P450 enzymes.
To determine whether Dap1 interacts directly with
P450s or other sterol biosynthetic enzymes, we purified
Dap1 fused to the tandem affinity purification tag, Dap1-
TAP. Yeast cells expressing dap1-TAP from the endoge-
nous promoter were lysed in detergent, and Dap1-TAP
was purified by affinity chromatography. Dap1-TAP pro-
tein complexes in the final eluate were subjected to su-Cell Mcrose velocity gradient centrifugation, and gradient frac-
tions were analyzed by SDS-PAGE and silver staining
(Figure 2A). Proteins in fractions 12–14 from a parallel gra-
dient were pooled and identified by mass spectrometry
(Sanders et al., 2002). These fractions contained three
proteins: Dap1-TAP, Erg11, and Erg5. Contaminating pro-
teins in the total eluate did not cofractionate with Dap1-
TAP or the P450 enzymes, suggesting that Dap1 binds
directly to one or both of these P450 enzymes. To confirm
these interactions, we assayed binding of Dap1 to epi-
tope-tagged Erg11 or Erg5 by coimmunoprecipitation.
Dap1-HA copurified with both Erg11-Myc and Erg5-TAP,
demonstrating that Dap1 forms a complex with both
P450 enzymes in fission yeast (Figures 2B and 2C). Bind-
ing was specific, as neither Erg11 nor Erg5 bound to Sre1
in the ERmembrane. Collectively, these data demonstrate
that Dap1 stably binds to Erg11 and Erg5, is required for
sterol synthesis, and functions as a positive regulator of
two different cytochrome P450 enzymes in vivo.
Dap1 homologs from other organisms are pentacoordi-
nate heme-binding proteins predicted to utilize a con-
served tyrosine residue in their C terminus for heme bind-
ing (Ghosh et al., 2005; Mallory et al., 2005; Min et al.,
2005). To test whether fission yeast Dap1 is a heme-bind-
ing protein, we purified soluble recombinant DTM-Dap1
lacking the N-terminal transmembrane segment. In paral-
lel, we purified DTM-Dap1 Y138F that was predicted notetabolism 5, 143–149, February 2007 ª2007 Elsevier Inc. 145
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peroxidase assays revealed that Dap1, but not Dap1
Y138F, bound heme (Figure 3A). To determine whether
heme binding is required for Dap1 function, we expressed
HA-dap1 and HA-dap1 Y138F on a plasmid from the con-
stitutive CaMV promoter in dap1D cells and examined
steady-state sterol levels in these cells. Both wild-type
and Y138F mutant Dap1 were expressed at equal levels
in yeast (Figure S2). The strain harboring the wild-type
HA-dap1 plasmid showed wild-type sterol levels as
anticipated. However, similar to dap1D, yeast carrying
the HA-dap1 Y138F plasmid accumulated 24-methylene
lanosterol, ergosta-5,7,24(28)-trienol, and ergosta-5,7-
dienol, reflecting defects in Erg11 and Erg5 (Figure 3B).
These data indicate that dap1 Y138F is a loss-of-function
mutation and that Dap1 function requires bound heme.
The human genome contains two homologs of fission
yeast dap1+, called progesterone receptor membrane
component 1 and 2 (PGRMC1 and PGRMC2). To date,
only PGRMC1 has been characterized (Crudden et al.,
2006; Gerdes et al., 1998; Ghosh et al., 2005; Raza
et al., 2001; Min et al., 2005). Tissue expression profiles
of human PGRMC1 revealed that it was broadly ex-
pressed, with high levels present in liver and adrenal
Figure 3. Dap1 Requires Heme
(A) 6xHis-DTM-Dap1 protein and the Y138F mutant were purified from
E. coli and subjected to SDS-PAGE. Protein was visualized by Gel-
Code blue staining (Protein, upper lane) or analyzed for heme content
by measuring peroxidase activity in the gel (Heme, lower lane).
(B) Sterols were extracted and analyzed as described in Figure 1B from
wild-type and dap1D yeast containing plasmids expressing HA-dap1
or HA-dap1 Y138F from the CaMV promoter. Data are the average
of three independent isolates. Error bars represent one standard
deviation.146 Cell Metabolism 5, 143–149, February 2007 ª2007 Elseviergland, two sites of abundant cytochrome P450 activity
(Figure S3). To determine whether PGRMC1 is required
for cholesterol synthesis in mammals, we used retroviral
infection to generate human HEK293 cells that stably ex-
pressed RNA hairpins designed to knock down expres-
sion of PGRMC1 mRNA. Analysis of mRNA and protein
levels revealed that the cell line PGR1-1, but not PGR1-
2, had reduced expression ofPGRMC1mRNA and protein
(Figure 4A). We performed sterol analysis on HEK293,
PGR1-1, and PGR1-2 cells grown in the presence of in-
creasing concentrations of mevalonate to maximize flux
through the cholesterol pathway. HEK293 and PGR1-2
cells accumulated the intermediate lanosterol when sup-
plemented with mevalonate (Figure 4B). This level of lano-
sterol did not affect cell growth after 24 hr (Figure 4B,
lower panel). Interestingly, PGR1-1 cells accumulated lan-
osterol at levels 3-fold higher than control cells. Elevated
lanosterol is toxic to cells, and accumulation of lanosterol
correlated with the death of PGR1-1 cells at concentra-
tions of mevalonateR30 mM. No other significant differ-
ences in cellular sterols were observed among the cell
lines, suggesting that PGRMC1 function was required
specifically for the demethylation of lanosterol by the
Erg11 human homolog, Cyp51A1. Unlike ergosterol syn-
thesis, cholesterol synthesis only requires one cyto-
chrome P450, Cyp51A1, and thus no homolog of Erg5 ex-
ists in mammals. Microsomes fromHEK293, PGR1-1, and
PGR1-2 cells treated with 0 or 40mMmevalonate for 10 hr
contained equal amounts of Cyp51A1, suggesting that
PGRMC1 affected Cyp51A1 activity and not protein
stability as reported for S. cerevisiae Dap1p (Figure S4)
(Mallory et al., 2005).
To test whether PGRMC1 binds to Cyp51A1 in mam-
mals as in yeast, we coexpressed FLAG-PGRMC1 and
Cyp51-6xMyc by transient transfection in HEK293 cells.
PGRMC1 was quantitatively recovered in coimmuno-
precipitations from these cells and the majority of
Cyp51A1 copurified (Figure 4C). In a parallel experiment,
FLAG-PGRMC1did not bind Site-1 protease, amembrane
protein required for activation of mammalian SREBP,
demonstrating the specificity of PGRMC1 for Cyp51A1
(Espenshade et al., 1999). Dap1 bound to both P450
enzymes in fission yeast, yet the amino acid sequence iden-
tity between Erg11 and Erg5 is no greater than that
betweenErg11andothermammalianP450enzymes.Conse-
quently, we hypothesized that PGRMC1 may bind to a
broad spectrum of P450 enzymes. To test this hypothe-
sis, we assayed binding of FLAG-PGRMC1 to three func-
tionally diverse human P450 enzymes: Cyp3A4, required
for xenobiotic metabolism and clearance of 50% of all
known drugs (Rendic, 2002); Cyp7A1, the rate-limiting en-
zyme in bile acid synthesis (Russell, 2003); and Cyp21A2,
a progesterone 21-hydroxylase required for production
of glucocorticoids and mineralocorticoids (Ortiz de Mon-
tellano, 2005). PGRMC1 bound efficiently to all three pro-
teins (Figure 4D). Collectively, these data demonstrate
that PGRMC1 is required for Cyp51A1 activity in choles-
terol synthesis and that PGRMC1 may function as a com-
mon regulator of cytochrome P450 enzymes in mammals.Inc.
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Cytochrome P450-Binding Protein Re-
quired for Cholesterol Synthesis
(A) Total RNA (25 mg) and cell extracts (50 mg)
from wild-type, PGR1-1, and PGR1-2
HEK293 cell lines were subjected to northern
(top panel) and immunoblot analysis (bottom
panel) with anti-PGRMC1 7948 polyclonal
serum.
(B) Top panel: On day 0, wild-type, PGR1-1,
and PGR1-2 cells were seeded at 53 105 cells
per well in six-well plates in DMEM+10%FCS.
On day 2, cells were refed with DMEM + 5% li-
poprotein-deficient serum (LPDS) and the indi-
cated concentration of mevalonate. After 10 hr,
cells were harvested and subjected to sterol
analysis by gas chromatography. Ergosterol
(5 mg) was added to each sample as an internal
standard. Data represent the average of two
replicates. Error bars equal one standard devi-
ation. Bottom panel: On day 0, wild-type,
PGR1-1, and PGR1-2 cells were seeded at
3 3 106 cells per 10 cm dish in DMEM + 10%
FCS. On day 1, cells were refed with DMEM +
5% LPDS and the indicated concentration
of mevalonate. After 24 hr, cells were stained
with crystal violet.
(C and D) On day 0, HEK293 cells were seeded
at 2.4 3 106 cells per 10 cm dish. On day 1,
cells were transfected with 2 mg each of the
indicated CMV-driven plasmids expressing
FLAG-PGRMC1, Myc-tagged protein, or empty vector. After 24 hr, cells were harvested, and detergent-solubilized microsomes were subjected
to immunoprecipitation with FLAG-agarose. Unbound (U) and bound (B) fractions were subjected to immunoblot analysis with polyclonal
anti-Myc IgG or anti-FLAG-HRP. Equal amounts of unbound and bound fractions were analyzed.Our studies demonstrate that Dap1/PGRMC1 is a con-
served hemoprotein required for the activity of cyto-
chrome P450 enzymes in eukaryotic sterol synthesis. Sev-
eral lines of evidence suggest that Dap1/PGRMC1 has
a broad function in cytochrome P450 biology: (1) Dap1 is
required for the activity of two P450 enzymes from differ-
ent families, Erg11(Cyp51) and Erg5(Cyp61); (2) Dap1/
PGRMC1 binds to P450 enzymes from five different fam-
ilies; and (3) PGRMC1 has been shown to affect Cyp21 ac-
tivity in vivo and in vitro (Laird et al., 1988; Min et al., 2005).
Known P450-interacting proteins, NADPH cytochrome
P450 oxidoreductase and cytochrome b5, supply elec-
trons to cytochrome P450 through transient interactions
and are present in catalytic amounts (Estabrook et al.,
1971). In contrast, Dap1/PGRMC1 forms a stable, stoi-
chiometric complex with P450 enzymes. Unlike the hexa-
coordinate heme protein cytochrome b5, Dap1 function
requires binding of pentacoordinate heme. This property
suggests that Dap1 does not donate electrons to the
P450 enzyme. Previous studies hypothesized that S. cer-
evisiae Dap1p may act as a heme chaperone and donate
heme to newly synthesized Erg11p because deletion of
DAP1 reduced Erg11 protein levels (Ghosh et al., 2005;
Mallory et al., 2005). However, our data favor a model in
which Dap1/PGRMC1 is a stable component of a cyto-
chrome P450 enzyme complex and Dap1/PGRMC1 per-
forms an unrecognized, heme-dependent function in the
P450 catalytic cycle. Further studies will be required toCell Mdefine both the mechanism and the structural basis of
PGRMC1 function. Mutations in cytochrome P450 en-
zymes cause multiple human diseases, including congen-
ital adrenal hyperplasia (Cyp21A2) and hypercholesterol-
emia (Cyp7A1) (Nebert and Russell, 2002). Our findings
suggest that mutations inPGRMC1may lead tomore sub-
tle forms of these diseases. In addition, identification of
a regulator of P450 enzymes has important implications
for drug metabolism research, as polymorphisms in
PGRMC1 may contribute to pharmacogenetic variation
observed between individuals, and we are actively inves-
tigating this possibility (Evans and Relling, 1999).
EXPERIMENTAL PROCEDURES
Yeast cell culture, immunoblot analysis, northern analysis, and sterol
analysis were performed as previously described with minor modifica-
tions (Hughes et al., 2005). A complete description of materials,
mammalian cell culture, recombinant protein purification, and other
methods is available in the Supplemental Experimental Procedures.
Dap1-TAP Purification and Sucrose Gradient Fractionation
The Dap1-TAP purification was conducted as described previously,
except that digitonin was substituted for NP-40 in the lysis, wash,
and elution buffers (Rigaut et al., 1999). The eluate was subjected to
sucrose velocity gradient centrifugation (15%–40% sucrose w/v) to
separate Dap1-TAP protein complexes from other nonspecific inter-
acting proteins. Fractions from duplicate gradients were TCA precipi-
tated and analyzed by SDS-PAGE or mass spectrometry (Sanders
et al., 2002). Proteins identified in Dap1-TAP protein complexesetabolism 5, 143–149, February 2007 ª2007 Elsevier Inc. 147
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wild-type, untagged yeast eluate.
For coimmunoprecipitations, yeast or transfected mammalian cells
were lysed in TAP lysis buffer plus protease inhibitors. Cleared lysates
were incubated with antibody and IgG-Sepharose overnight at 4C
and washed with TAP lysis buffer containing 0.1% (w/v) digitonin,
and bound protein was subjected to immunoblot analysis.
Retroviral RNAi Production
Retroviruses containing shRNAshomologous to regions in the 30UTRof
human PGRMC1 mRNA (GenBank accession number NM_006667)
were produced according to manufacturer’s instructions (Open Bio-
systems). Briefly, LinX cells seeded at 3 3 106 cells per 10 cm dish
on day 0 were transfected on day 1 with 10 mg of either pSM2 Expres-
sion Arrest clone v2HS_90636 or v2HS_90640. On day 2, the cells
were refed with 8 ml of fresh HEK293 medium. On day 4, the virus-
containing supernatant was harvested by filtering and stored at 80C
until further use.
Generation of PGRMC1 RNAi Knockdown Cell Line
On day 0, HEK293 cells were seeded at 5 3 105 cells per 6 cm dish in
2mlHEK293medium.Onday 1, cells were infectedwith 100ml of super-
natant containing retrovirus expressing either PGRMC1 shRNA clone
v2HS_90636 or v2HS_90640 along with a puromycin-resistance
marker.Onday 2, cellswere refedwithHEK293mediumsupplemented
with 3 mg/ml puromycin for selection of cells stably expressing the indi-
cated shRNA. Cells were refed every 3–4 days until only single clones
remained. For each shRNA construct, the clones were pooled and ex-
panded to establish twomixed population cell lines, designated PGR1-
1 and PGR1-2. PGR1-1 has reduced PGRMC1 RNA and protein levels
and expresses shRNA clone v2HS_90636. PGR1-2, which expresses
shRNA clone v2HS_90640, does not have reduced PGRMC1 levels
and serves as the negative control RNAi cell line. Both cell lines were
maintained in HEK293medium supplementedwith 3 mg/ml puromycin.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, and four figures and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/
5/2/143/DC1/.
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